Anika Therapeutics’ (ANIK) “Buy” Rating Reaffirmed at B. Riley Financial

Anika Therapeutics (NASDAQ:ANIK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at B. Riley Financial in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $17.00 price objective on the biotechnology company’s stock, down from their previous price objective of $23.00. B. Riley Financial‘s price target indicates a potential upside of 26.87% from the stock’s previous close.

A number of other research firms have also recently issued reports on ANIK. Zacks Research cut shares of Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Wall Street Zen raised Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Barrington Research set a $21.00 price target on Anika Therapeutics in a research note on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anika Therapeutics in a research note on Monday, September 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.00.

Read Our Latest Stock Analysis on Anika Therapeutics

Anika Therapeutics Stock Performance

NASDAQ:ANIK opened at $13.40 on Monday. The stock has a market capitalization of $179.56 million, a price-to-earnings ratio of -103.07, a PEG ratio of 9.57 and a beta of 0.21. The firm has a fifty day simple moving average of $19.66 and a two-hundred day simple moving average of $16.36. Anika Therapeutics has a 12 month low of $9.01 and a 12 month high of $22.88.

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The biotechnology company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.13). Anika Therapeutics had a negative net margin of 1.43% and a positive return on equity of 1.87%. The company had revenue of $30.59 million during the quarter, compared to the consensus estimate of $29.44 million. Equities analysts predict that Anika Therapeutics will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Anika Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in shares of Anika Therapeutics by 22.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,282 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,873 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Anika Therapeutics by 4.0% during the 1st quarter. Hsbc Holdings PLC now owns 50,292 shares of the biotechnology company’s stock valued at $729,000 after buying an additional 1,951 shares in the last quarter. Corient Private Wealth LP raised its holdings in Anika Therapeutics by 6.6% during the 2nd quarter. Corient Private Wealth LP now owns 35,415 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 2,192 shares during the period. Meeder Asset Management Inc. purchased a new stake in Anika Therapeutics during the 2nd quarter worth about $37,000. Finally, Palumbo Wealth Management LLC boosted its position in shares of Anika Therapeutics by 11.4% in the third quarter. Palumbo Wealth Management LLC now owns 44,656 shares of the biotechnology company’s stock valued at $878,000 after acquiring an additional 4,580 shares during the period. Institutional investors own 91.53% of the company’s stock.

About Anika Therapeutics

(Get Free Report)

Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.

Further Reading

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.